Rivas, Elisa I.
Linares, Jenniffer
Zwick, Melissa
Gómez-Llonin, Andrea
Guiu, Marc
Labernadie, Anna
Badia-Ramentol, Jordi
Lladó, Anna http://orcid.org/0000-0001-5884-7114
Bardia, Lídia http://orcid.org/0000-0003-2232-683X
Pérez-Núñez, Iván http://orcid.org/0000-0002-2907-1991
Martínez-Ciarpaglini, Carolina
Tarazona, Noelia
Sallent-Aragay, Anna
Garrido, Marta
Celià-Terrassa, Toni http://orcid.org/0000-0002-0615-8744
Burgués, Octavio
Gomis, Roger R. http://orcid.org/0000-0001-6473-2858
Albanell, Joan http://orcid.org/0000-0003-1239-4580
Calon, Alexandre http://orcid.org/0000-0002-3398-6131
Funding for this research was provided by:
Fundación Cellex (0)
Fundación Científica Asociación Española Contra el Cáncer (6884)
Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (CB16/12/00241, PI18/00006, PI21/00002, PI17/00211, CP16/00151, MS16/00151, CPII21/00012)
Generalitat de Catalunya (2017 SGR 507)
Article History
Received: 20 July 2021
Accepted: 17 August 2022
First Online: 9 September 2022
Competing interests
: J.A. has received consulting fees and honoraria from Seagen, Pfizer, AstraZeneca, Lilly, Merck, Roche, Gilead, Novartis and Daiichi-Sankyo, receives royalties from a licensed patent to Biocartis (EP11382270.4; Mutations in the epidermal growth factor receptor gene) and holds stock options from Inbiomotion. Other authors declare no competing interests.